Hypermarcas (OTCMKTS:HYPMY) Stock Price Down 6% – Time to Sell?

Hypermarcas (OTCMKTS:HYPMY)’s stock price dropped 6% during trading on Monday . The company traded as low as $3.75 and last traded at $3.75. 2,014 shares were traded during mid-day trading, a decline of 91% from the average session volume of 23,060 shares. The stock had previously closed at $3.99.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Zacks Research upgraded shares of Hypermarcas to a “hold” rating in a research report on Wednesday, April 29th. Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy”.

Hypermarcas Price Performance

The company has a market cap of $2.84 billion, a PE ratio of 8.41 and a beta of 0.71. The business has a 50 day moving average of $4.15 and a 200 day moving average of $4.38.

Hypermarcas (OTCMKTS:HYPMY) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $0.10 EPS for the quarter. Hypermarcas had a net margin of 19.41% and a return on equity of 14.08%. The business had revenue of $383.13 million during the quarter. Sell-side analysts forecast that Hypermarcas will post 0.53 EPS for the current fiscal year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.